English press releases

Transforming the Future of Medicine with RNA-Based Therapies

New Novotech Whitepaper Explores Innovations and Impact of this precise, versatile and scalable technology. BOSTON–(BUSINESS WIRE)– Novotech, the global full-service clinical Contract Research Organization (CRO)...

Balmain Launches Balmain Beauty With a New Luxury Fragrance Collection: Les Éternels

Creative Director Olivier Rousteing Builds on Balmain’s Legendary Fashion and Perfume History to Change the Meaning of Beauty for the Future PARIS–(BUSINESS WIRE)– Balmain announces...

1NCE Wins at the 2024 SaaS Awards

The SaaS Awards recognize the leading innovations of software-as-a-service solutions across a wide range of use cases in 56 categories. 1NCE wins “Best SaaS Innovation...

Thales and L&T Technology Services Expand Collaboration to Provide Innovative Business Models to Customers

New contract builds on 20-year relationship with engineering and R&D firm, L&T Technology Services Limited (LTTS) Strategic collaboration will see LTTS use the Thales Sentinel...

JT Group to Acquire Vector Group Ltd.

TOKYO–(BUSINESS WIRE)– Japan Tobacco Inc. (JT) (the “Company”) (TSE: 2914) announces today that the JT Group has reached an agreement with Vector Group Ltd. (“VGR”),...

Rimini Street Earns 2024 Tech Cares Award from TrustRadius

Rimini Street and its privately funded charitable program recognized for its commitment to corporate social responsibility and community impact LAS VEGAS–(BUSINESS WIRE)– Rimini Street, Inc....

ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy

Submission based on DESTINY-Breast06 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a statistically significant and clinically meaningful improvement in progression-free...

IFF to Webcast Fireside Chat at Barclays Global Consumer Staples Conference on Sept. 5

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer...

Bentley Systems Announces the Finalists of the 2024 Going Digital Awards

Winners to be Announced on October 9 at Bentley’s 2024 Year in Infrastructure and Going Digital Awards Event in Vancouver EXTON, Pa.–(BUSINESS WIRE)– Bentley Systems,...

PhireLink deploys Adtran’s fiber access solution to bridge Louisiana’s digital divide

News summary: Leading broadband internet service provider needed flexible AI-driven platform to connect rural areas Adtran’s access technology enables PhireLink to rapidly scale its fiber-based...

H.I.G. Capital Completes Investment in Axis Europe Limited

LONDON–(BUSINESS WIRE)– H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $64 billion of capital under management, is pleased to announce that one of...

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Ad hoc announcement pursuant to Art. 53 LR  Nemluvio® (nemolizumab) is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine...

Allianz Achieves Record Profits in First Half 2024

Group Fully on Track for Full-Year Outlook, Powered by Strong Fundamentals MUNICH–(BUSINESS WIRE)– August 8, 2024 This press release features multimedia. View the full release...

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

– Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today – – CASGEVY is one of the...

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval...